Protagonist's $50M milestone; Swiss biotech raises $27M; Kymera halts a PhI
Plus, news from CEPI and ProJenX:
Protagonist Therapeutics records a $50M milestone: The company said Wednesday that it’s getting a $50 million milestone from its agreement with Johnson & Johnson. The milestone was triggered by the third patient being dosed in a Phase III trial evaluating a psoriasis treatment. Protagonist said it expects to launch additional Phase III studies for the oral peptide next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.